• Advancing gastrointestinal health naturally

    Our Gastrointestinal ReProgramming (GaRP) product is a microbiome-targeted multi-component dietary supplement that has been designed to address the primary underlying factors associated with gastrointestinal disorders. More >>

  • Pitt Street Research Life Sciences Conference Presentation

    Anatara Lifesciences CEO, Mr Steven Lydeamore, recently presented to investors at the Pitt Street Research Life Sciences Conference in Sydney. View the Announcement & Slide Deck and Presentation at these links.

  • Anatara supports Antibiotic Awareness Week

    Anatara Lifesciences supports the global campaign to raise awareness of antibiotic resistance and to encourage best practices among the general public, health workers and policy makers to avoid the further emergence and spread of antibiotic resistance. More >>

  • Statistically significant GaRP in vivo animal studies

    Anatara’s unique Gastrointestinal ReProgramming (GaRP) dietary supplement completes preclinical testing, demonstrating it can treat inflammatory gastrointestinal disease and may promote mucosal healing in recent in vivo animal studies and further positive in vitro studies. More >>

  • Anatara Lifesciences brings new hope for sufferers of IBS

    Since 1997, April has been designated as Irritable Bowel Syndrome (IBS) Awareness Month to focus attention on important health messages about IBS. Anatara is developing a new dietary supplement for sufferers of IBS that will help manage their condition and associated symptoms. More >>

Company description

Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. The Company is focused on building a pipeline of human gastrointestinal health products.

Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Recent coverage



More Events


Investors Home